Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 16 systematic review(s)/meta-analysis(es). ^[1-16]
• Lasmiditan, particularly at a dose of 200 mg, was effective in achieving pain freedom at 2 hours post-dose and sustained pain freedom at 24 hours, although some studies indicated no significant difference between the 100 mg and 200 mg dosages for pain relief at 2 hours.
• In comparison to triptans, lasmiditan was generally less effective in achieving pain freedom and pain relief at 2 hours; however, it demonstrated comparable efficacy to gepants such as rimegepant and ubrogepant while being associated with a higher incidence of adverse events.
• Lasmiditan was effective for the acute treatment of menstrual migraine (MM), showing effectiveness similar to sumatriptan, with the 200 mg dose proving more effective than the 100 mg dose but also associated with a higher risk of adverse events.
• Lasmiditan was associated with a high incidence of adverse events, particularly at the 200 mg dose, with common adverse effects including dizziness, somnolence, paresthesia, fatigue, and nausea; this higher dose also showed an increased risk of adverse events compared to the 100 mg dose.
• Central nervous system-related adverse events, such as dizziness and somnolence, were the most frequently reported, while no significant cardiovascular-related adverse events were noted, which is relevant for patients with cardiovascular risks.
• Lasmiditan was not specifically mentioned for preventive treatment in MM, which is addressed by frovatriptan and calcitonin gene-related peptide antibodies (CGRP) monoclonal antibodies (erenumab, galcanezumab).
• The comparison of dosages indicated that lasmiditan 200 mg was generally more effective than 100 mg for achieving pain freedom at both 2 hours and 24 hours, although the higher dosage was also associated with a greater incidence of adverse events.